Literature DB >> 12564839

Evaluation of whole blood serotonin and plasma and urine 5-hydroxyindole acetic acid in diagnosis of carcinoid disease.

R S Carling1, T J Degg, K R Allen, N D S Bax, J H Barth.   

Abstract

BACKGROUND: Carcinoid disease is an uncommon disorder resulting from tumours of the enterochromaffin cells. Current biochemical investigation usually involves the measurement of 5-hydroxyindole-3-acetic acid (5-HIAA) in 24-h urine collections. Because of the problems associated with urine collections (i.e. inconvenience, accuracy of collection and requirement for preservatives) two alternative markers, fasting plasma 5-HIAA and whole blood serotonin (5-hydroxytryptamine), have been studied. METHODS AND
RESULTS: Whole blood serotonin concentration and plasma and urine 5-HIAA concentrations were measured by high-performance liquid chromatography in 31 patients suspected of having carcinoid and 26 known carcinoid patients. Receiver operator characteristic curve analysis of the data showed no statistical difference between the three markers (P>0.01) with regard to their discriminating function. However, fasting plasma 5-HIAA assay showed greater stability than whole blood serotonin assay and is more convenient for the patient than a 24-h urine collection. At a cut-off value of 118 nmol/L plasma 5-HIAA assay showed a sensitivity of 89%, a specificity of 97% and a test efficiency of 93%. Whole blood serotonin assay was further limited by its saturation in platelets at 40 nmol/10(9) platelets which made it less suitable for monitoring the treatment of carcinoid disease.
CONCLUSION: Fasting plasma 5-HIAA concentration provides a more convenient screening test for carcinoid and overcomes the problems associated with 24-h urine collections, without any loss of diagnostic precision.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12564839     DOI: 10.1177/000456320203900605

Source DB:  PubMed          Journal:  Ann Clin Biochem        ISSN: 0004-5632            Impact factor:   2.057


  20 in total

1.  Small Bowel Neuroendocrine Tumors.

Authors:  Catherine G Tran; Scott K Sherman; James R Howe
Journal:  Curr Probl Surg       Date:  2020-05-15       Impact factor: 1.909

Review 2.  Multimodal management of neuroendocrine liver metastases.

Authors:  Andrea Frilling; Georgios C Sotiropoulos; Jun Li; Oskar Kornasiewicz; Ursula Plöckinger
Journal:  HPB (Oxford)       Date:  2010-08       Impact factor: 3.647

3.  Biochemical prognostic indicators for pancreatic neuroendocrine tumors and small bowel neuroendocrine tumors.

Authors:  Christine S Landry; Keith Cavaness; Scott Celinski; John Preskitt
Journal:  Gland Surg       Date:  2014-11

4.  Increase of urinary 5-hydroxyindoleacetic acid excretion but not serum chromogranin A following over-the-counter 5-hydroxytryptophan intake.

Authors:  Tisha Joy; Grace Walsh; Sonya Tokmakejian; Stan Hm Van Uum
Journal:  Can J Gastroenterol       Date:  2008-01       Impact factor: 3.522

Review 5.  Workup of Gastroenteropancreatic Neuroendocrine Tumors.

Authors:  Joseph S Dillon
Journal:  Surg Oncol Clin N Am       Date:  2020-04       Impact factor: 3.495

Review 6.  The biological characterization of neuroendocrine tumors: the role of neuroendocrine markers.

Authors:  P Ferolla; A Faggiano; G Mansueto; N Avenia; M G Cantelmi; P Giovenali; M L Del Basso De Caro; F Milone; G Scarpelli; S Masone; F Santeusanio; G Lombardi; G Angeletti; A Colao
Journal:  J Endocrinol Invest       Date:  2008-03       Impact factor: 4.256

Review 7.  Radiology of the neuroendocrine neoplasms of the gastrointestinal tract: a comprehensive review.

Authors:  Sundeep Malla; Pawan Kumar; Kumble Seetharama Madhusudhan
Journal:  Abdom Radiol (NY)       Date:  2020-09-22

Review 8.  Serotonin pharmacology in the gastrointestinal tract: a review.

Authors:  D T Beattie; J A M Smith
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2008-04-09       Impact factor: 3.000

Review 9.  Biochemical Testing in Neuroendocrine Tumors.

Authors:  Vidya Aluri; Joseph S Dillon
Journal:  Endocrinol Metab Clin North Am       Date:  2017-06-12       Impact factor: 4.741

10.  Clinical correlates of blood serotonin levels in patients with mastocytosis.

Authors:  N M Kushnir-Sukhov; E Brittain; L Scott; D D Metcalfe
Journal:  Eur J Clin Invest       Date:  2008-12       Impact factor: 4.686

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.